Organization | Catholic University of Sacred Heart, Rome

Catholic University of Sacred Heart, Rome Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Rome Italy (1921)

Organization Overview

First Clinical Trial

2002

NCT02090504

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Allergy Department, Catholic University of the Sacred Heart | Andrea Giaccari | Catholic University | Catholic University, Italy | Catholic University of Rome | Catholic University of sacred Heart | Catholic University of Sacred Heart | Catholic University of the Sacred Heart | Catholic University of the Sacred Heart - Rome | Catholic University of the Sacred Heart, Rome | Catholic University Rome | Chatolic University of Sacred Heart, Roma | Department cardiovascular diseases A. Gemelli Polyclinic , University Sacred Heart in Rome | Department of Internal Medicine, Catholic University of Rome | Division of Oncologic Gynecology, Fondazione Policlinico Gemelli | Fondazione di Ricerca e Cura Giovanni Paolo II , Campobasso , Italy | Fondazione Policlinico A. Gemelli | Istituto di Reumatologia Complesso Integrato Columbus - Policlinico Gemelli Roma | Luca Cardone | Policlinico Universitario A.Gemelli | Policlinico Universitario A. Gemelli | Policlinico Universitario A. Gemelli - Rome - Italy | Policlinico Universitario Agostino Gemelli | The Catholic University of the Sacred Heart | University Sacred Heart in Rome

Active Ingredients

Drugs in Phase 4 Trials (27)

amiodarone (cordarone) (2 trials)

atazanavir (reyataz) (2 trials)

beclomethasone (vanceril) (1 trial)

carvedilol (coreg) (1 trial)

clopidogrel (plavix) (2 trials)

darunavir (prezista) (1 trial)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

epoprostenol (veletri) (1 trial)

ertapenem (invanz) (1 trial)

fentanyl (Innovar) (3 trials)

heparin (liquaemin) (1 trial)

lamivudine (epivir) (4 trials)

maraviroc (selzentry) (1 trial)

ondansetron (zofran) (1 trial)

oxazepam (serax) (1 trial)

ramipril (altace) (2 trials)

ranolazine (ranexa) (1 trial)

remifentanil (ultiva) (2 trials)

rifaximin (xifaxan) (1 trial)

ringer's lactate (1 trial)

ritonavir (Norvir) (3 trials)

sodium chloride (3 trials)

sodium oxybate (xyrem) (1 trial)

telmisartan (micardis) (1 trial)

ticagrelor (brilinta) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 3 Trials (28)

abacavir (ziagen) (2 trials)

acetylsalicylic acid (aspirin) (3 trials)

adenosine (Adenocard) (1 trial)

bictegravir (Biktarvy) (1 trial)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (1 trial)

dapagliflozin (farxiga) (1 trial)

dolutegravir (tivicay) (1 trial)

drospirenone (Yasmin) (3 trials)

emtricitabine (emtriva) (2 trials)

ethinyl estradiol (Estinyl) (3 trials)

fluorouracil (efudex) (2 trials)

irinotecan (Camptosar) (1 trial)

ketamine (ketalar) (1 trial)

lactobacillus brevis (1 trial)

lactobacillus reuteri (2 trials)

leucovorin (2 trials)

methylprednisolone (medrol) (1 trial)

montelukast (singulair) (1 trial)

neomycin (1 trial)

nitroprusside (nipride) (1 trial)

oxaliplatin (eloxatin) (1 trial)

rimabotulinumtoxinB (Myobloc) (1 trial)

sitagliptin (januvia) (4 trials)

tenofovir alafenamide (genvoya) (1 trial)

thiamine (1 trial)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (27)

3-glycosyl-3-odemethylthiocolchicine (1 trial)

acetylcysteine (mucomyst) (1 trial)

baclofen (lioresal) (1 trial)

bevacizumab (avastin) (1 trial)

carboplatin (paraplatin) (2 trials)

celecoxib (celebrex) (1 trial)

colchicine (colbenemid) (1 trial)

crocus (2 trials)

darleukin (1 trial)

decitabine (dacogen) (1 trial)

dexmedetomidine (precedex) (1 trial)

golodirsen (Vyondys 53) (1 trial)

human fecal microbiota (Reybota) (4 trials)

indocyanine green (ic-green) (2 trials)

l19il2 (1 trial)

l-epigallocatechin (1 trial)

paclitaxel (taxol) (1 trial)

polyglutamate camptothecin (1 trial)

propionyl l-carnitine (1 trial)

raltegravir (isentress) (1 trial)

sargramostim (leukine) (1 trial)

temozolomide (temodar) (1 trial)

tenofovir (viread) (1 trial)

topotecan (hycamtin) (1 trial)

trabectedin (yondelis) (1 trial)

vancomycin (Vancocin) (2 trials)

vatiquinone (1 trial)

Drugs in Phase 1 Trials (5)

estradiol (progynon depot) (2 trials)

follitropin alfa (Gonal-F) (1 trial)

lutropin alpha (luveris) (1 trial)

myoinositol (4 trials)

urofollitropin (Metrodin) (1 trial)

Drugs in Other Trials (18)

alpha-lipoic acid (1 trial)

carbon dioxide (dry ice) (1 trial)

dopamine (intropin) (1 trial)

epinephrine (levophed) (1 trial)

folic acid (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

levobupivacaine (chirocaine) (1 trial)

liraglutide (victoza) (1 trial)

medroxyprogesterone (provera) (1 trial)

melatonin (1 trial)

morphine (2 trials)

oxygen (1 trial)

polyethylene glycol (1 trial)

poractant alfa (curosurf) (1 trial)

propofol (diprivan) (1 trial)

ribavirin (virazole) (1 trial)

rocuronium (zemuron) (1 trial)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acid-Base Imbalance (Phase 4)

Acquired Immunodeficiency Syndrome (Phase 4)

Acute Coronary Syndrome (Phase 4)

Acute Kidney Injury (Phase 4)

Acute Lung Injury (Phase 3)

Alcoholism (Phase 4)

Amyotrophic Lateral Sclerosis (Phase 2)

Anterior Wall Myocardial Infarction (Phase 2)

Arteriosclerosis (Phase 2)

Asthma (Phase 3)

Atrial Fibrillation (Phase 3)

Back Pain (Phase 2)

Breast Neoplasms (Phase 4)

Carcinoma, Ovarian Epithelial (Phase 2)

Cardiovascular Diseases (Phase 3)

Cataract (Phase 3)

Cholecystolithiasis (Phase 4)

Cholelithiasis (Phase 4)

Clostridium Infections (Phase 2)

Colitis (Phase 2)

Colitis, Ulcerative (Phase 2)

Colorectal Neoplasms (Phase 3)

Communicable Diseases (Phase 2)

Confusion (Phase 4)

Constipation (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 4)

Diverticular Diseases (Phase 4)

Diverticulum (Phase 4)

Endometrial Neoplasms (Phase 2)

Endometriosis (Phase 2)

Enterocolitis, Pseudomembranous (Phase 2)

Fibrosis (Phase 2)

Gallstones (Phase 4)

Genetic Diseases, Inborn (Phase 2)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Heart Failure (Phase 4)

Helicobacter Infections (Phase 2)

HIV Infections (Phase 4)

Homocystinuria (Phase 2)

Hyperplasia (Phase 3)

Hypersensitivity (Phase 4)

Hypersensitivity, Immediate (Phase 4)

Hypertension (Phase 2)

Infarction (Phase 4)

Infections (Phase 2)

Infertility (Phase 1)

Infertility, Female (Phase 1)

Insulin Resistance (Phase 4)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Alcoholic (Phase 2)

Low Back Pain (Phase 2)

Lung Injury (Phase 3)

Macular Degeneration (Phase 2)

Motor Neuron Disease (Phase 2)

Mucositis (Phase 3)

Muscular Dystrophies (Phase 4)

Muscular Dystrophy, Duchenne (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 2)

Myocardial Stunning (Phase 4)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Ocular Hypertension (Phase 2)

Ovarian Neoplasms (Phase 2)

Overweight (Phase 4)

Pharyngitis (Phase 4)

Polycystic Ovary Syndrome (Phase 3)

Prostatic Hyperplasia (Phase 3)

Rectal Neoplasms (Phase 3)

Renal Insufficiency (Phase 4)

Respiratory Distress Syndrome (Phase 3)

Retinal Degeneration (Phase 2)

Sclerosis (Phase 2)

Status Epilepticus (Phase 3)

Stomatitis (Phase 3)

Substance Withdrawal Syndrome (Phase 4)

Syndrome (Phase 4)

Thromboembolism (Phase 3)

Ulcer (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 86
# of Trial APIs: 105